好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Characterizing Local Field Potentials in Primary Dystonia
Movement Disorders
P2 - Poster Session 2 (11:45 AM-12:45 PM)
16-003

We aim to characterize the prevalence of peaks in the power spectral density of the local field potentials (LFPs) of patients with primary dystonia treated with deep brain stimulation (DBS).

DBS is an effective therapy for medication refractory primary dystonia. DBS programming for dystonia is challenging due to the lack of real-time visual feedback and the delayed therapeutic response. There is emerging evidence that LFP analysis can guide this process.

We conducted a retrospective study of patients with primary dystonia who underwent bilateral globus pallidus internus (GPi) DBS with a sensing-enabled system (Medtronic Percept). LFP recordings were collected in the clinic setting in the DBS OFF state while patients were at rest. We define the spectral bands using the canonical definitions: beta from 12 Hz to 30 Hz and gamma from 30 to 100 Hz. Spectral band powers were extracted using the UF BRAVO platform with visual-based frequency peak detection. Descriptive statistics were performed to characterize frequency distribution and trends over time.

51 subjects (28 female, 23 male) with dystonia and GPi DBS were included for analysis. 28 (54.9%) demonstrated a beta band peak and 23 (45.1%) demonstrated a gamma band peak at any point during DBS programming. 29 participants had longitudinal recordings which demonstrated persistent beta peaks in 22 (75.8%) and persistent gamma peaks in 16 (55.2%). Additionally, 20.7% initially had no beta peak and later developed one, 27.6% had a beta peak that disappeared over time, and 27.6% had both. 34.5% initially had no gamma peak and later developed one, 13.8% had a gamma peak that disappeared over time and 6.9% had both.

We provide an overview of basal ganglia electrophysiology in a large cohort of primary dystonia patients treated with DBS. Further research is needed to identify potential biomarkers that could guide neuromodulation strategies.

Authors/Disclosures
Melanie Gonzalez
PRESENTER
Miss Gonzalez has nothing to disclose.
Hunter J. Hutchinson Mr. Hutchinson has nothing to disclose.
Kara A. Johnson, PhD Dr. Johnson has nothing to disclose.
Jackson Cagle Jackson Cagle has nothing to disclose.
Matthew Remz, MD (University of Florida) Dr. Remz has nothing to disclose.
Coralie De Hemptinne, PhD The institution of Mrs. De Hemptinne has received research support from Alpha Omega. Mrs. De Hemptinne has received personal compensation in the range of $0-$499 for serving as a grant review with Michael J Fox foundation.
Joshua Wong, MD (University of Florida College of Medicine - Neurology) The institution of Dr. Wong has received research support from NIH.